donepezil


Also found in: Dictionary, Wikipedia.

donepezil

 [do-nep´ĕ-zil]
a reversible acetylcholinesterase inhibitor, used as the hydrochloride salt for treatment of mild to moderate symptoms of dementia of the Alzheimer type; administered orally.

donepezil

/do·nep·e·zil/ (do-nep´ĕ-zil) an acetylcholinesterase inhibitor used as the hydrochloride salt for the treatment of mild to moderate symptoms of dementia of the Alzheimer type; administered orally.

donepezil

(dō-nĕp′ə-zĭl′)
n.
A drug, C24H29NO3, that inhibits acetylcholinesterase and is used in its hydrochloride form to treat mild to moderate dementia caused by Alzheimer's disease.

donepezil

a reversible cholinesterase.
indication It is used to treat mild to moderate dementia in Alzheimer's disease.
contraindications Known hypersensitivity to this drug or to piperidine derivatives prohibits its use.
adverse effects Life-threatening effects include seizures and atrial fibrillation. Other adverse effects are dizziness, somnolence, fatigue, abnormal dreams, syncope, hypotension or hypertension, anorexia, urinary frequency, urinary tract infection, incontinence, rash, flushing, rhinitis, upper respiratory infection, cough, pharyngitis, cramps, and arthritis. Common side effects include insomnia, headache, nausea, vomiting, and diarrhea.

donepezil

Aricept® Neurology A cholinesterase inhibitor used to maintain cognition in Alzheimer's disease Contraindications Succinylcholine-type anesthesia, sick sinus syndrome, seizures Adverse events N&V, insomnia, muscle cramps, anorexia, fatigue. See Alzheimer's disease.

donepezil

An ACETYLCHOLINESTERASE inhibitor drug used in Alzheimer's disease and other forms of dementia to increase the amount of ACETYLCHOLINE available for nerve transmission. A brand name is Aricept.

Donepezil

A drug commonly prescribed for Alzheimer's disease that provides temporary improvement in cognitive functions for some patients with mild-to-moderate forms of the disease.
Mentioned in: Dementia
References in periodicals archive ?
USA], Sep 30 ( ANI ): A team of researchers has recently suggested that a drug - donepezil - is most likely to enhance concentration, memory, alertness and moods in patients with Alzheimer's dementia.
Indian pharmaceutical firm Zydus Cadila (NSE: CADILAHC) has been granted final approval from the US Food and Drug Administration (FDA) to market Donepezil Hydrochloride tablets in the strength of 23 mg, the company said on Friday.
We are excited that with the new available dosage strengths patients with moderate to severe Alzheimer's disease, who are currently stabilized on Aricept, donepezil hydrochloride (10 mg) can now start combination therapy directly with NAMZARIC.
Kognitif bulgulara yonelik Donepezil 10 mg/gun baslandi.
The usual initial adult dose for oral use is 3 mg of donepezil hydrochloride once daily.
Compared with the olfaction-intact patient, those with baseline deficits in sense of smell on a simple scratch-and-sniff test had significantly more improvements in episodic memory after 12 weeks of donepezil (Aricept) in a placebo-controlled, double-blind randomized pilot study, he reported at the annual meeting of the American Association for Geriatric Psychiatry.
The 12-week, phase II study randomized 274 subjects to either placebo, 10 mg donepezil, or 5 or 10 mg ABT-126.
High doses of donepezil or memantine may be the next step in achieving better results than standard pharmacologic treatments for AD.
After donepezil tablets and venlafaxine extended-release capsules, this was our third new product launch in the United States within 21 days," says chairman Habil Khorakiwala.
1) Furthermore, donepezil hydrochloride (Aricept), a drug commonly used in patients with Alzheimer's disease, has been reported to cause high-grade A-V block as well as symptomatic sinus bradycardia, presumably due to its inhibition of acetylcholinesterase.
The US Food and Drug Administration (FDA) has approved donepezil HCl 23-mg tablets (Aricept; Eisai, Inc and Pfizer, Inc) for the once-daily treatment of moderate to severe Alzheimer's disease (AD).
27 November 2009 - Danish pharma company H Lundbeck A/S (CPH: LUN) said today that it started a phase II study with the candidate drug Lu AE58054 as add-on to donepezil in patients with moderate Alzheimer's disease.